Further processing options
Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) bl...
Saved in:
Journal Title: | Annals of Oncology |
---|---|
Authors and Corporations: | , , , , |
In: | Annals of Oncology, 30, 2019, p. ii62 |
Type of Resource: | E-Article |
Language: | English |
published: |
Elsevier BV
|
Subjects: |